疫苗(英文) Pub Date : 2013-02-22 DOI: 10.4236/WJV.2013.31002

J. Reyna-Figueroa, Diana PerezPeña-Rosas, Patricia Galindo-Delgado, A. E. Limón-Rojas, V. Madrid-Marina

{"title":"Association between an Incomplete Vaccination Schedule and Nosocomial Sepsis among Children with Cancer","authors":"J. Reyna-Figueroa, Diana PerezPeña-Rosas, Patricia Galindo-Delgado, A. E. Limón-Rojas, V. Madrid-Marina","doi":"10.4236/WJV.2013.31002","DOIUrl":"https://doi.org/10.4236/WJV.2013.31002","url":null,"abstract":"Background: Patients with cancer constitute a \u0000special group where immunization programs are often interrupted to begin \u0000treatment with chemotherapy. Sepsis is one of the main complications in this \u0000group. Methods: A hospital-based case-control study matched by age was carried out among \u0000subjects ≤ 9 years of age \u0000with cancer diagnosis. Children with cancer without sepsis and children with \u0000surgical pathology were included as controls; children with sepsis were included \u0000as cases. A bivariate logistic regression was used to determine the factors \u0000associated to nosocomial sepsis, and odds ratios were calculated with 95% \u0000confidence intervals. The percentage of attributable risk was calculated for \u0000the variables included in the final model. Results: Nineteen children with cancer and sepsis and 83 controls were included. Twelve \u0000(44%) caseshad an incomplete vaccination schedule according to their age. The \u0000association force between incomplete schedule and sepsis was 10.1 (95% CI, 3 - 36; p Conclusions: Approximately, 20% to 65% of the cases of serious nosocomial infection \u0000can be associated to an incomplete vaccination schedule. Strategies should be \u0000implemented to improve the general pediatric population’s vaccination status \u0000before a serious disease, such as cancer or another chronic condition \u0000preventing the application of vaccines, develops.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70893038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Vaccines in Non-Small Cell Lung Cancer 非小细胞肺癌的疫苗研究

疫苗(英文) Pub Date : 2013-02-22 DOI: 10.4236/WJV.2013.31004

L. Corrales-Rodríguez, N. Blais, D. Soulières

引用次数: 1

High-Dose Intra-Dermal Hepatitis B Vaccine in a Liver Transplant Patient Who Failed Prior Intramuscular Vaccination: A Brief Case Report 先前肌肉注射疫苗失败的肝移植患者皮下注射高剂量乙型肝炎疫苗:一个简短的病例报告

疫苗(英文) Pub Date : 2013-02-22 DOI: 10.4236/WJV.2013.31003

S. Dhillon, K. Sampath, C. Moore, A. Dosanjh, D. Thiel

引用次数: 1

Montanide TM Gel01 ST Adjuvant Enhances PRRS Modified Live Vaccine Efficacy by Regulating Porcine Humoral and Cellular Immune Responses Montanide TM Gel01 ST佐剂通过调节猪体液和细胞免疫反应增强PRRS修饰活疫苗的效力

疫苗(英文) Pub Date : 2013-02-22 DOI: 10.4236/WJV.2013.31001

Xiangdong Li, A. Galliher-Beckley, J. Nietfeld, K. Faaberg, Jishu Shi

{"title":"Montanide TM Gel01 ST Adjuvant Enhances PRRS Modified Live Vaccine Efficacy by Regulating Porcine Humoral and Cellular Immune Responses","authors":"Xiangdong Li, A. Galliher-Beckley, J. Nietfeld, K. Faaberg, Jishu Shi","doi":"10.4236/WJV.2013.31001","DOIUrl":"https://doi.org/10.4236/WJV.2013.31001","url":null,"abstract":"Porcine reproductive and \u0000respiratory syndrome (PRRS) is a devastating disease caused by the PRRS virus. \u0000The MontanideTM class of flexible polymeric adjuvants has recently \u0000been shown to enhance protective immunity against PRRSV infection in piglets \u0000when used in combination with PRRS modified live vaccines (MLV). In this study, \u0000we explored the efficacy and immunological mechanisms of protection of \u0000MontanideTM Gel01 ST (Gel01) adjuvanted modified live PRRSV vaccine \u0000in pigs challenged with two genetically distinct strains of PRRSV. Gel01-MLV reduced \u0000lymph node pathology scores in pigs challenged with VR-2332 (parental strain of \u0000MLV vaccine) but not that in pigs challenged with MN184A (heterologous strain), when compared to that in \u0000pigs vaccinated with un-adjuvanted MLV. Pigs vaccinated with Gel01-MLV had \u0000higher levels of PRRS-specific antibodies, as measured by IDEXX ELISA and virus \u0000neutralizing antibodies, after vaccination and VR-2332 challenge. In addition, \u0000pigs vaccinated with Gel01-MLV had decreased levels of IFN-γ, IL-10, and T-regulatory lymphocytes in the blood as compared to \u0000that in pigs vaccinated with MLV alone. Interestingly, we found that addition \u0000of Gel01 did not change the profile of other T lymphocyte populations after \u0000PRRSV challenge. These results demonstrate that the MLV adjuvanted with Gel01 \u0000provides enhanced protection against homologous PRRSV infection, possibly by \u0000regulating the production of PRRSV-specific antibodies and cytokines involved \u0000in the development of T-regulatory cells. Thus, Gel01 ST is a promising adjuvant that can \u0000be formulated with PRRSV MLV vaccines to reduce disease severity and tissue \u0000damage caused by PRRSV infection in pigs.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70892980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing IMT504:一种新的有效的狂犬病疫苗佐剂，可显著节省剂量

疫苗(英文) Pub Date : 2012-11-28 DOI: 10.4236/WJV.2012.24025

A. Montaner, Analia De Nichilo, Jose Rodriguez, A. Hernando-Insúa, J. Fló, R. López, V. Sierra, C. Paolazzi, O. Larghi, D. Horn, J. Zorzópulos, F. Elías

{"title":"IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing","authors":"A. Montaner, Analia De Nichilo, Jose Rodriguez, A. Hernando-Insúa, J. Fló, R. López, V. Sierra, C. Paolazzi, O. Larghi, D. Horn, J. Zorzópulos, F. Elías","doi":"10.4236/WJV.2012.24025","DOIUrl":"https://doi.org/10.4236/WJV.2012.24025","url":null,"abstract":"Background: Rabies virus infection causes encephalitis, which is almost always fatal. Vaccination can be extremely effective at preventing disease but is prohibitively costly. Vaccine formulations allowing dose-sparing and fewer inoculations with faster antibody response would be extremely desirable. IMT504, an immunostimulatory non-CpG oligo-deoxynucleotide, is a highly potent vaccine adjuvant. Methods: Human and rat antibody measurements, and rat chal-lenge studies were performed. Results: In rats, highly effective immune responses with IMT504 were observed even after diluting vaccine up to 1/625. In highly lethal, live intracerebral rabies challenge studies, protection occurred even with extremely dilute vaccine plus IMT504. In humans, antibody titers developed faster and were significantly higher with IMT504-adjuvanted diluted vaccine vs non-adjuvanted vaccine (full strength or diluted). All five administered IMT504-adjuvanted diluted vaccine reached protective antibodies (≥0.5 IU/ml) after the second injection. After the third injection, individuals receiving IMT504-adjuvanted diluted vaccine reached levels approximately 10 times higher than controls (M ± SEM: 31.0 ± 10.9 vs 3.40 ± 0.99 IU/ml). Conclusions: These data suggest that IMT504 may allow fewer inoculations, highly significant dose-sparing of vaccine, rapid antibody production and protection from rabies. Extensive clinical studies are necessary to confirm if the use of IMT504 will permit significantly greater access to highly effective life-saving rabies vaccines.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70893341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Persistence of Pleural Effusions and Empyemas after Pneumococcal Conjugate Vaccine Implementation in Uruguay 乌拉圭肺炎球菌结合疫苗接种后胸腔积液和脓胸的持续存在

疫苗(英文) Pub Date : 2012-11-28 DOI: 10.4236/WJV.2012.24024

M. Estevan, L. Martínez, Edith Arreisengor, M. Hortal

引用次数: 1

Safety and Tolerability of a 13-Valent Pneumococcal Conjugated Vaccine Distributed in the Public Immunization Program of the Municipality of Campos dos Goytacazes, Rio de Janeiro, Brazil 巴西里约热内卢Campos dos Goytacazes市公共免疫规划中分配的13价肺炎球菌结合疫苗的安全性和耐受性

疫苗(英文) Pub Date : 2012-11-28 DOI: 10.4236/WJV.2012.24026

C. Kury, A. Wilken, R. Henriques, Renata de Carvalho Salles, Wilza Abreu de Brito, M. Kury, Rafael Pessanha de Sá, Felipe Pessanha de Sá

{"title":"Safety and Tolerability of a 13-Valent Pneumococcal Conjugated Vaccine Distributed in the Public Immunization Program of the Municipality of Campos dos Goytacazes, Rio de Janeiro, Brazil","authors":"C. Kury, A. Wilken, R. Henriques, Renata de Carvalho Salles, Wilza Abreu de Brito, M. Kury, Rafael Pessanha de Sá, Felipe Pessanha de Sá","doi":"10.4236/WJV.2012.24026","DOIUrl":"https://doi.org/10.4236/WJV.2012.24026","url":null,"abstract":"From september to december, 2010, we have assessed the frequency and occurrence of adverse events to Pneumo-coccal conjugated 13-valent vaccine (PCV-13) in the Public vaccination program of the municipality of Campos dos Goytacazes, State of Rio de Janeiro, the unique city in Brazil that has introduced this vaccine in it’s immunization schedule. This study analyzed 1001 toddlers who have received PCV-13 at 3, 5 and 7 months and a booster dose at 12 months. We observed a total of 514 local and systemic events in 303 subjects (30.2% of 1001 infants). The most reported systemic events were irritability (18.8%) and fever or = 38.5°C (8.8%), loss of appetite (8.4%). Erythema (11.2%) and local pain (9.4%) were the most reported local events. Other events reported were diarrhea (6.2%), increased sleep (5.1%), edema and induration (4.8%), decreased sleep (4.3%), vomiting (1.4%), eruption (1.2%) urticaria (0.8%), prurience (0.8%), lymphadenopathy (0.2%) and hypersensitivity reaction (0.2%). There wasn’t any reported case of convulsion or Hospital admission. When stratified by each dose, irritability (systemic) and erythema (local) were the most common events reported at the first and fourth dose, although fever < 38.5°C (systemic) and pain (local) were the most common at second and third doses. Results were close to those encountered in product monograph. In our study, PCV-13 was secure in pneumococcal disease prevention and well tolerated.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70892942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer 基于鞭毛表达muc1的治疗性肿瘤疫苗在侵袭性乳腺癌模型中的疗效

疫苗(英文) Pub Date : 2012-08-03 DOI: 10.4236/WJV.2012.23015

Nathalie Machluf, R. Arnon

引用次数: 8

Purification of Dengue Virus Particles by One-Step Ceramic Hydroxyapatite Chromatography 陶瓷羟基磷灰石一步色谱法纯化登革病毒颗粒

疫苗(英文) Pub Date : 2012-08-03 DOI: 10.4236/WJV.2012.23020

Y. Kurosawa, M. Saito, Shintaro Kobayashi, T. Okuyama

引用次数: 14

Epidemic Outbreaks in Plovdiv Region (Bulgaria) of Vaccine-Preventable Diseases: Measles, Mumps, Hepatitis A 保加利亚普罗夫迪夫地区疫苗可预防疾病的流行:麻疹、腮腺炎、甲型肝炎

疫苗(英文) Pub Date : 2012-08-03 DOI: 10.4236/WJV.2012.23023

N. Vatev, M. Stoycheva, A. Petrov, Rayna Velcheva

{"title":"Epidemic Outbreaks in Plovdiv Region (Bulgaria) of Vaccine-Preventable Diseases: Measles, Mumps, Hepatitis A","authors":"N. Vatev, M. Stoycheva, A. Petrov, Rayna Velcheva","doi":"10.4236/WJV.2012.23023","DOIUrl":"https://doi.org/10.4236/WJV.2012.23023","url":null,"abstract":"Aim: To analyze the reasons for epidemic outbreaks of measles, mumps and viral hepatitis A and to propose measures to prevent them in future. Materials and methods: Тhe incidence of measles, mumps and hepatitis A in Plovdiv region was studied for the period 2006-2010. An analysis of the age structure of the patients was made, while taking into account the time for routine immunization performed against measles and mumps (first and second dose). Results: In 2006-2009 single cases of measles were found occasionally, but in 2010 they were 2787 (incidence 395/100,000). Most of them (51%) were for ages 13 months-12years, 27%-0-13 months and 11%-13 to 18 years. The incidence of mumps for 2006-2010 varied widely, and has increased significantly in 2007 (130/100,000) and 2008 (169/100,000). The majority of patients (over 34%) during the epidemics were aged 13 months-12years, and over 26% of them-13-19 years. For the period 2006-2010 the incidence of hepatitis A ranged from 2.98/100, 000 (2009) to 426/100,000 (2006). Over 50% of the cases involved children aged up to 9 years. For the three diseases over 80% of patients were individuals of Roma origin. Conclusions: 1. Epidemic spread of measles in 2010 was mainly due to shortcomings in the routine immunization carried as a prevention of the disease. 2. There are two reasons for the outbreak of mumps: А) Failure to administer the second vaccine dose at 12 years in Bulgaria until 2001. B) Shortcomings in routinely performed immunization. 3. The extremely high incidence of hepatitis A in 2006 (and in the rest of the years) is due to the lack of routine immunization. 4. Essential for the outbreaks in all three diseases are the poor hygienic living conditions, the low social status and the lack of health promotion of the population at risk 5. To prevent future outbreaks of the diseases hereby in question, we suggest it is appropriate: А) To introduce compulsory immunization against hepatitis A; B) To carry out periodic catch-up vaccination campaigns against measles and mumps.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70892842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

疫苗(英文)最新文献